Figure 1:

Computed tomography imaging shows initial response to combination dabrafenib and trametinib and subsequent progression

A. CT scan of the chest at baseline prior to dabrafenib plus trametinib therapy demonstrated a dominant consolidated mass (asterisk) in the right lower lobe with heterogenous CT density and invasion into the right atrium (arrowhead), and right hilar and subcarinal lymphadenopathy (arrows).

B. CT scan at 13 weeks of therapy demonstrated a marked response to therapy with significant decrease of the dominant mass (asterisk) and lymph nodes (arrows).

C. CT scan at 21 weeks of therapy demonstrated continued response in the dominant right lower lobe lesion (asterisk) but progressive disease with increased bilateral hilar and subcarinal lymphadenopathy (arrows), multiple new lung nodules (arrowheads) and a new left chest wall nodule (large arrow).